Many small molecule inhibitors have been approved as cancer therapeutics, but they can confer mutation-based drug resistance and many potential cancer targets remain “undruggable”.
One emerging cancer therapeutic strategy that shows promise for drug development is the use of targeted protein degradation (TPD). This approach has many advantages, including the ability to aim at previously inaccessible cancer targets using small molecules, called degraders, that trigger ubiquitin-dependent degradation of specific proteins.
In this webinar, you will hear from Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, who will discuss efforts to synthesize and characterize small molecule degraders of cancer targets, including kinases and transcriptional regulators.
This webinar will benefit anyone who wants to stay up to date on an innovative technology in a rapidly growing area of research for cancer therapeutic development.
What you will learn:
- How advances in targeted protein degradation can harness a cell’s degradation machinery to break down key cancer proteins
- About proteomics methods that led to an open-access curated library of small molecule compounds that degrade protein kinases
- How to find valuable leads for the development of selective degraders of understudied cancer targets